ArticleFrontiers in pharmacology2025
Cre recombinase affects calcium dynamics already in young mice.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ckmm-Cre transgenic mice maintain phenotypic and cardiac mitochondrial homeostasis during ketogenic feeding.Molecular and cellular biochemistry · 2026Article
- A modification of retrograde Langendorff-perfusion to increase the yield of CaFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Cre/LoxP system is widely used in cardiovascular research to generate mouse models with tissue-specific inactivation of target genes. Studies have reported that expression of Cre recombinase under the αMHC promoter leads to age-dependent cardiotoxicity with ventricular hypertrophy, fibrosis and ventricular dysfunction at 6 months of age. This study explores the impact of Cre expression on intracellular Ca Methods: Mice expressing Cre under the αMHC promoter (CRE) were compared to wild-type (WT) controls. Ventricular cardiomyocytes (VCMs) were isolated by the Langendorff method. Ca Results: At 3 months, CRE mice showed no evidence of cardiac hypertrophy. Ventricular or atrial weights and VCM size were not different between CRE and WT mice. The same applied to protein levels of SERCA2a, NCX1, Cav1.2, PLN and its phosphorylated form PLN pThr17. Nevertheless Ca Conclusion: As early as 3 months of age, Cre expression in VCMs leads to changes in Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.